(Rac)-Ruxolitinib D9

Modify Date: 2024-01-04 22:50:59

Use of (Rac)-Ruxolitinib D9

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor[1].

Name	(Rac)-Ruxolitinib D9

Description	(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK
In Vivo	(Rac)-Ruxolitinib氘代物
References	[1]. Yaoyu CHEN, et al. Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor. Patent WO2021102258A1

Molecular Formula	C₁₇H₉D₉N₆
Molecular Weight	315.42